burosumab X-linked hypophosphatemia
Selected indexed studies
- Burosumab for Pediatric X-Linked Hypophosphatemia. (Curr Osteoporos Rep, 2021) [PMID:33970403]
- Efficacy and Safety of Burosumab in X-linked Hypophosphatemia. (J Clin Endocrinol Metab, 2023) [PMID:37497620]
- X-Linked Hypophosphatemia. (, 1993) [PMID:22319799]
_Worker-drafted node — pending editorial review._
Connections
burosumab X-linked hypophosphatemia is a side effect of
Sources
- Burosumab for Pediatric X-Linked Hypophosphatemia. (2021) pubmed
- Efficacy and Safety of Burosumab in X-linked Hypophosphatemia. (2023) pubmed
- X-Linked Hypophosphatemia. (1993) pubmed
- Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease. (2020) pubmed
- Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries. (2022) pubmed
- Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study. (2024) pubmed
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. (2018) pubmed
- X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline. (2025) pubmed
- Real-world effectiveness of burosumab vs oral phosphate and active vitamin D in adults with X-linked hypophosphatemia. (2025) pubmed
- What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review. (2022) pubmed